SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
SAN DIEGO, July 26, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical-stage biotech company with proprietary technology platforms...
SAN DIEGO, July 21, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW), a clinical stage biotech company with proprietary technology platforms...
Company’s Proprietary TAAP Prodrug Delivery and Overdose Technology Aims to Stem The Opioid Abuse Epidemic
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce” or the “Company”) (NASDAQ: ENSC, OTC: ENSCW) today announced that the Company will begin trading its common stock...
SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (OTC: LACQ, LACQW) today announced that, in connection with the closing of its previously announced...
Covistat to present pre-clinical data at American Thoracic Society annual meeting, May 14-19, 2021
NEW YORK and SAN DIEGO, April 29, 2021 (GLOBE NEWSWIRE) -- Ensysce Biosciences, Inc. (“Ensysce”) and Leisure Acquisition Corp. (“LACQ”) (NASDAQ: LACQ, LACQU, LACQW) , a special purpose...
Additional Contract Broadens and Further Strengthens Customer Product Portfolio
WILMINGTON, Del., March 16, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: